Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Accumulated Expenses (2020 - 2022)

Historic Other Accumulated Expenses for Ovid Therapeutics (OVID) over the last 3 years, with Q1 2022 value amounting to $139167.0.

  • Ovid Therapeutics' Other Accumulated Expenses fell 7933.01% to $139167.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $139167.0, marking a year-over-year decrease of 7933.01%. This contributed to the annual value of $546464.0 for FY2021, which is 23011.79% up from last year.
  • Latest data reveals that Ovid Therapeutics reported Other Accumulated Expenses of $139167.0 as of Q1 2022, which was down 7933.01% from $546464.0 recorded in Q4 2021.
  • In the past 5 years, Ovid Therapeutics' Other Accumulated Expenses ranged from a high of $2.0 million in Q2 2021 and a low of $119940.0 during Q3 2021
  • Moreover, its 3-year median value for Other Accumulated Expenses was $271314.0 (2020), whereas its average is $488409.9.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 62103.43% in 2021, then tumbled by 7933.01% in 2022.
  • Over the past 3 years, Ovid Therapeutics' Other Accumulated Expenses (Quarter) stood at $165536.0 in 2020, then skyrocketed by 230.12% to $546464.0 in 2021, then plummeted by 74.53% to $139167.0 in 2022.
  • Its Other Accumulated Expenses was $139167.0 in Q1 2022, compared to $546464.0 in Q4 2021 and $119940.0 in Q3 2021.